利用CRISPR/Cas系统对血友病B小鼠进行基因纠正的初步探索

血友病B是人类常见的X染色体遗传的隐性遗传疾病,目前对于遗传疾病的治疗还没有很好的办法,通过基因治疗可以实现对遗传病的彻底治愈。本研究利用高效基因编辑技术CRISPR/Cas系统,对血友病B小鼠尝试基因修复进行初步的探索,将突变的凝血因子IX(Factor IX,FIX)基因进行同源替换,修复为正常序列。本研究中将同一种纯合突变类型的小鼠交配之后得到的受精卵,进行细胞核显微注射。对收集到的8枚囊胚的基因组中的靶位点,进行巢氏PCR扩增,直接进行测序检测基因型序列。检测结果为4枚囊胚的基因被成功编辑,其中3枚囊胚为靶序列的基因敲除突变,而有1枚囊胚成功进行同源重组,实现基因纠正。     

Cas9蛋白变体VQR高效识别水稻NGAC前间区序列邻近基序

成簇的规律间隔短回文重复序列及CRISPR相关蛋白(clustered regularly interspaced short palindromic repeats/CRISPR-associated 9, CRISPR/Cas9)系统是近年来发展起来并被广泛应用的第三代基因组编辑工具。但是,该系统的酿脓链球菌Cas9(Streptococcus pyogenes, SpCas9)仅能识别NGG前间区序列邻近基序(protospacer adjacent motif, PAM),极大地限制了基因组编辑的范围。SpCas9变体VQR(D1135V/R1335Q/T1337R)在水稻中可识别NGAA、NGAG和NGAT PAM,但尚不清楚是否能识别NGAC PAM。本研究利用改进后的CRISPR/VQR系统对水稻中3个相对低效的VQR靶位点NAL1-Q1、NAL1-Q2和LPA1-Q进行了编辑,结果表明改进后的CRISPR/VQR系统可以高效编辑这3个靶位点,编辑效率分别为9.75%、43.90%和29.26%。为了明确改进后的CRISPR/VQR系统对NGAC PAM的识别情况,本研究选择水稻叶片宽度调控基因NARROW LEAF 1 (NAL1)中的NAL-C位点和蜡质合成基因GLOSSY1 (GL1)中的GL1-C位点进行基因编辑,并获得57株转基因水稻。靶位点PCR扩增及测序结果表明,NAL1-C和GL1-C靶标位点突变的植株分别为27株和44株,突变率分别为47.36%和77.19%;其中NAL1-C/GL1-C双突变植株为26株,双突变率为45.61%。进一步分析表明,CRISPR/VQR系统造成的突变有4种类型,分别为杂合突变、双等位突变、嵌合体突变和纯合突变,其中以杂合突变和双等位突变为主。这些结果表明,改进的CRISPR/VQR系统可以高效编辑水稻NGAC PAM位点,并产生丰富的突变类型。本研究为水稻及其他植物相关基因NGAC PAM位点的编辑提供了理论依据。     

利用CRISPR/Cas9技术产生肌肉特异表达Cas9的小鼠胚胎

目的通过CRISPR/Cas9技术获得肌肉特异性表达Cas9蛋白小鼠胚胎,为建立肌肉特异表达Cas9小鼠动物模型奠定基础。方法设计小鼠Rosa26位点sgRNA并通过体外酶切验证活性,同时使用同源重组构建肌肉特异性同源打靶载体;通过显微注射将Rosa26sgRNA与Cas9蛋白注射到小鼠胚胎,通过PCR及测序检测胚胎的编辑情况,同时移植到假孕母鼠体内,待其生产;将同源打靶载体与Rosa26sgRNA和Cas9一起注射到小鼠胚胎,通过PCR检测整合情况。结果体外酶切实验表明,体外转录的sgRNA与Cas9蛋白联合可对靶位点产生编辑作用;成功构建了肌肉特异性同源打靶载体Donor-SP-px459;通过原核注射获得Rosa26基因编辑胚胎,经移植获得Rosa26基因编辑小鼠;注射同源打靶载体后,成功获得肌肉特异表达Cas9蛋白的基因打靶小鼠胚胎。结论利用CRISPR/Cas9技术,成功获得Rosa26基因编辑胚胎和小鼠,并获得了肌肉特异性表达Cas9蛋白小鼠胚胎,为利用基因打靶构建肌肉特异表达Cas9的小鼠动物模型奠定基础。     

基于新的CRISPR/Cas9技术实现斑马鱼LHX9基因的快速编辑及对F0突变体性腺发育的初筛

目的:CRISPR/Cas9系统在斑马鱼的反向遗传学中的到了广泛应用,但突变基因的表型观察往往需要在突变鱼系的F1中进行,费时较长。LHX9作为LIM家族的一种转录因子,在胚胎早期的泌尿生殖嵴中有广泛分布;且LHX9基因敲除的小鼠存在性腺发育不良。本研究拟通过一种新的CRISPR/Cas9基因编辑技术,采用四条sgRNA对LHX9基因进行VASA转基因斑马鱼的基因敲除,以观察该基因缺陷对斑马鱼性腺发育的影响。方法:利用新的CRISPR/Cas9技术,设计四条针对斑马鱼LHX9基因3号外显子的20bp的sgRNA,通过非克隆体外转录得到靶位点的四条sgRNA。将以上靶位点的四条sgRNA与Cas9核酸酶蛋白同时注射入单细胞期的斑马鱼胚胎内,利用PCR鉴定突变型类型和突变比例。通过对LHX9基因突变体的VASA转基因斑马鱼进行荧光观察,发现LHX9基因缺陷的斑马鱼性腺发育的情况。结果:靶向Exon 3的四条sgRNA可成功编辑斑马鱼LHX9基因,敲除效率高达82%,Sanger测序发现产生10种不同的移码突变类型。通过该方法对VASA转基因斑马鱼的LHX9基因进行编辑,发现LHX9基因突变导致dph6的的斑马鱼原始生殖细胞增殖和迁移受到影响。结论:基于4条sgRNA注射的CRISPR/Cas9技术,可以快速地产生具有突变表型的G0斑马鱼,具有应用潜力。LHX9基因敲除导致原始生殖细胞的发育和迁移受到影响,提示该基因参与了斑马鱼早期性腺的发育。     

利用CRISPR/Cas9技术对人多能干细胞进行高效基因组编辑

CRISPR/Cas9技术提供了一个全新的基因组编辑体系。本文利用CRISPR/Cas9平台,在人胚胎干细胞株中对选取的一段特定基因组区域进行了多种基因组编辑：通过在基因编码框中引入移码突变进行基因敲除;通过单链DNA提供外源模板经由同源重组定点敲入FLAG序列;通过同时靶向多个位点诱导基因组大片段删除。研究结果表明CRISPR/Cas9可以对多能干细胞进行高效基因编辑,获得的突变干细胞株有助于对基因和基因组区域的功能进行分析和干细胞疾病模型的建立。     

人类胚胎单碱基编辑治疗遗传疾病的研究

基因编辑技术是当今生物学研究领域最为重要的颠覆性技术之一,以CRISPR/Cas9系统为核心的基因编辑工具被广泛应用于包括人类体细胞、生殖细胞编辑相关的医学研究领域。虽然CRISPR/Cas9系统可以高效编辑靶基因,但其精准编辑能力依赖于效率极低的同源重组方式,这极大限制了其定点编辑的能力与应用范围,所以寻找一种能高效引入点突变的新型基因编辑工具具有重大的应用价值。以CRISPR/Cas9系统为基础的单碱基编辑系统可以在基因组靶位点实现精准、高效的C/G和T/A碱基间的转换,其编辑能力已经在动植物、人体细胞以及人类胚胎中得到证实。利用单碱基编辑技术,有望对人类超过70%的相关遗传性致病位点进行修复。现就人类胚胎单碱基编辑治疗遗传疾病的最新研究进展进行综述和展望。     

CRISPR-Cas9技术在遗传性疾病基因治疗中的研究进展

CRISPR-Cas9是一种能够降解入侵病毒或噬菌体DNA的适应性免疫防御系统。CRISPR/Cas9系统被开发成为新一代的基因编辑技术,其特点是构建相对简单、成本相对较低,可灵活快速地用于基因敲除、基因增补等操作。CRISPR/Cas9技术在人类遗传病治疗中具有重大的潜在意义,已被广泛应用于遗传病相关研究中。我们简要综述了近年来CRISPR/Cas9基因编辑技术在地中海贫血、杜氏肌营养不良、帕金森症、Crygc基因突变引发的白内障、囊性纤维化、α1抗胰蛋白酶缺乏症、遗传性酪氨酸血症、血友病等遗传性疾病基因治疗中的研究进展。     

CRISPR/Cas9基因组编辑技术在番茄中的应用现状及展望北大核心CSCD

CRISPR/Cas9技术是一种能够快速对基因组靶位点进行特定DNA修饰的编辑工具。该文对近年来国内外有关CRISPR/Cas9技术在改善番茄农艺性状及提高生物、非生物胁迫抗性方面的研究进展进行综述,并集中讨论了CRISPR/Cas9面临的一些问题,为该基因编辑技术在番茄的种质创新及基因功能研究方面的应用提供参考。     

基于CRISPR/Cas9系统和增强ssODN重组建立tau-V337M小鼠模型

利用CRISPR/Cas9基因编辑技术建立tau-V337M突变的阿尔茨海默病(Alzheimer’s disease,AD)小鼠模型。通过设计和体外合成单向导RNAs(single guide RNAs,sgRNA)及单链寡核苷酸(single-stranded oligonucleotides,ssODN),将sgRNA、Cas9蛋白、ssODN注射到小鼠受精卵内,利用DNA切割和重组产生突变。为了提高重组效率,又在注射时添加Rad51蛋白。使用自然交配的雌鼠作为受体,将2细胞期的编辑胚胎进行单侧输卵管移植。研究发现通过添加Rad51蛋白可以获得较高的突变效率,在F0小鼠中获得了tau-V337M小鼠并进行扩繁,F0代tau-V337M小鼠可以将突变遗传给F1代。综上所述,本研究利用Cas9、ssODN和Rad51成功建立了首个tau-V337M基因位点突变的小鼠模型,为AD的研究和点突变模型制作提供了模型和方法基础。     

基于CRISPR/Cas9系统对斑马鱼hoxb4基因的编辑及其突变体基因型的初筛

采用高效基因编辑系统CRISPR/Cas9构建hoxb4基因敲除斑马鱼模型,进行hoxb4基因功能的研究。根据hoxb4基因的一号外显子的正义链及反义链设计3个长20 bp的sg RNA,分别靶向ExonⅠ的192#位点,244#位点及313#位点。化学合成sg RNA的寡核苷酸序列,经过酶切克隆进p T7-g RNA质粒中,构建g RNA的体外转录载体并通过体外转录得到靶位点的g RNA。将质粒p SP6-2s NLS-sp Cas9线性化然后在体外转录得到Cas9的m RNA并进行加A尾,将以上靶位点的g RNA与Cas9的m RNA共注射入单细胞期的斑马鱼胚胎内,提取基因组DNA,PCR扩增出目的基因片段并使用T7EI酶切测效,最后将PCR产物连入p MD19-T simple载体中,挑取阳性克隆进行菌落PC R鉴定,然后经Sanger测序检测突变类型。结果显示,靶位点的sg RN A寡核苷酸双链成功连入p T7-g RNA质粒中且序列正确;其中靶向ExonⅠ的313#位点的sg RNA可成功编辑斑马鱼hoxb4基因,T7 EⅠ检测其敲除效率高达26.5%,并测序得到4种阳性突变型。通过CRISPR/Cas9系统成功编辑斑马鱼hoxb4基因并测序鉴定其突变类型,为HOXb4基因功能的研究提供了可靠的基因敲除方法。     

Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes

Tyrosinase is the rate-limiting enzyme for the production of melanin pigmentation. In the mouse and other animals, homozygous null mutations in the Tyrosinase gene (Tyr) result in the absence of pigmentation, i.e. albinism. Here we used the CRISPR/Cas9 system to generate mono- and bi-allelic null mutations in the Tyr locus by zygote injection of two single-guide and Cas9 RNAs. Injection into C57BL/6N wild-type embryos resulted in one completely albino founder carrying two different Tyr mutations. In addition, three pigmentation mosaics and fully pigmented littermates were obtained that transmitted new mutant Tyr alleles to progeny in test crosses with albinos. Injection into Tyr heterozygous (B6CBAF1/J×FVB/NJ) zygotes resulted in the generation of numerous albinos and also mice with a graded range of albino mosaicism. Deep sequencing revealed that the majority of the albinos and the mosaics had more than two new mutant alleles. These visual phenotypes and molecular genotypes highlight the somatic mosaicism and allele complexity in founders that occurs for targeted genes during CRISPR/Cas9-mediated mutagenesis by zygote injection in mice.     

Simple generation of albino C57BL/6J mice with G291T mutation in the tyrosinase gene by the CRISPR/Cas9 system

Single nucleotide mutations (SNMs) are associated with a variety of human diseases. The CRISPR/Cas9 genome-editing system is expected to be useful as a genetic modification method for production of SNM-induced mice. To investigate whether SNM-induced mice can be generated by zygote microinjection of CRISPR/Cas9 vector and single-stranded DNA (ssDNA) donor, we attempted to produce albino C57BL/6J mice carrying the Tyr gene SNM (G291T) from pigmented C57BL/6J zygotes. We first designed and constructed a CRISPR/Cas9 expression vector for the Tyr gene (px330-Tyr-M). DNA cleavage activity of px330-Tyr-M at the target site of the Tyr gene was confirmed by the EGxxFP system. We also designed an ssDNA donor for homology-directed repair (HDR)-mediated gene modification. The px330-Tyr-M vector and ssDNA donor were co-microinjected into the pronuclei of 224 one-cell-stage embryos derived from C57BL/6J mice. We obtained 60 neonates, 28 of which showed the ocular albinism and absence of coat pigmentation. Genomic sequencing analysis of the albino mice revealed that the target of SNM, G291T in the Tyr gene, occurred in 11 mice and one founder was homozygously mutated. The remaining albino founders without Tyr G291T mutation also possessed biallelic deletion and insertion mutants adjacent to the target site in the Tyr locus. Simple production of albino C57BL/6J mice was provided by C57BL/6J zygote microinjection with px330-Tyr-M DNA vector and mutant ssDNA (G291T in Tyr) donor. A combination of CRISPR/Cas9 vector and optional mutant ssDNA could be expected to efficiently produce novel SNM-induced mouse models for investigating human diseases.     

One‐step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock‐in mice

Here, we describe a one‐step, in vivo CRISPR/Cas9 nuclease‐mediated strategy to generate knock‐in mice. We produced knock‐in (KI) mice wherein a 1.9‐kb DNA fragment bearing a pre‐arranged human B‐cell receptor heavy chain was recombined into the native murine immunoglobulin locus. Our methodology relies on Cas9 nuclease‐induced double‐stranded breaks directed by two sgRNAs to occur within the specific target locus of fertilized oocytes. These double‐stranded breaks are subsequently repaired via homology‐directed repair by a plasmid‐borne template containing the pre‐arranged human immunoglobulin heavy chain. To validate our knock‐in mouse model, we examined the expression of the KI immunoglobulin heavy chains by following B‐cell development and performing single B‐cell receptor sequencing. We optimized this strategy to generate immunoglobulin KI mice in a short amount of time with a high frequency of homologous recombination (30–50%). In the future, we envision that such knock‐in mice will provide much needed vaccination models to evaluate immunoresponses against immunogens specific for various infectious diseases.     

Female mice of DDK strain are fully fertile in the intersubspecific crosses with Mus musculus molossinus and M. m. castaneus

The female mice of DDK strain are almost infertile when mated with males from other strains. This phenomenon is caused by the early death of F1 embryos owing to the incompatibility system attributed to the ovum mutant (Om) locus on Chromosome (Chr) 11 and known as DDK syndrome. In the present study, DDK females were found to be fully fertile in the intersubspecific matings with the males of two wild mouse-derived strains, MOM (originated from Japanese wild mice, Mus musculus molossinus) and Cas (originated from Philippine wild mice, M. m. castaneus), indicating that no incompatibility exists between DDK oocytes and spermatozoa of MOM and Cas strains. Furthermore, this compatibility has been confirmed by the following two findings: (1) Normal fertility was shown by the two types of backcrosses, DDK females x F(1) (DDK female x MOM male) males and DDK females x F(1) (DDK female x Cas male) males; and (2) the offspring from these backcrosses segregated equally into the homozygotes and heterozygotes as genotyped by the microsatellite markers closely linked to Om locus. MOM and Cas strains would be useful for further investigations on the Om locus. On the other hand, the litter size of F(1) [C57BL/6Cr (B6) female x Cas male] females mated with B6 males was about half that of the mating with DDK males. It would be interesting to investigate whether this reduction in fertility is related to the Om locus or not.     

Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX

A mutant human factor IX with arginine at 338 residual changed to alanine (hFIXR338A) by site-directed mutagenesis was introduced into AAV vectors, and a recombinant adeno-associ-ated viral vector containing hFIXR338A, prepared by rHSV/AAV hybrid helper virus system, was directly introduced to the hind leg muscle of factor IX knock out mice. The expression and the biological activity of human factor IX mutant, hFIXR338A, and the immune response against it in the treated mice were assayed and detected. The results showed that (i) the high-level expression of human factor IX mutant protein, hFIXR338A, has been detected in rAAV-hFIXR338A treated hemophilia B mice and lasted more than 15 weeks; (ii) the clotting activity of hFIXR338A in plasma is 34.2%± 5.23%, which is remarkably higher than that of (14.27%±3.4%) of wild type hFIX treated mice in the activated partial thromboplastin assay; (iii) immune response against factor IX R338A was absent, with no factor IX mutant protein (hFIXR338A) inhibitors deve     

Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX

A mutant human factor IX with arginine at 338 residual changed to alanine (hFIXR338A) by site-directed mutagenesis was introduced into AAV vectors, and a recombinant adeno-associ- ated viral vector containing hFIXR338A, prepared by rHSV/AAV hybrid helper virus system, was directly introduced to the hind leg muscle of factor IX knock out mice. The expression and the biological activity of human factor IX mutant, hFIXR338A, and the immune response against it in the treated mice were assayed and detected. The results showed that (i) the high-level expression of human factor IX mutant protein, hFIXR338A, has been detected in rAAV-hFIXR338A treated hemophilia B mice and lasted more than 15 weeks; (ii) the clotting activity of hFIXR338A in plasma is 34.2%± 5.23%, which is remarkably higher than that of (14.27% ± 3.4%) of wild type hFIX treated mice in the activated partial thromboplastin assay; (iii) immune response against factor IX R338A was absent, with no factor IX mutant protein (hFIXR338A) inhibitors development in the treated mice; and (iv) no local or systemic side-effects and toxicity associated with the gene transfer were found. It demonstrated the potential use of treating hemophilia B by recombinant adeno-associated viral vectors with mutant hFIXR338A gene, an alternative strategy for hemophilia B gene therapy to wild-type human factor IX.     

Meiotic Cas9 expression mediates gene conversion in the male and female mouse germline

Highly efficient gene conversion systems have the potential to facilitate the study of complex genetic traits using laboratory mice and, if implemented as a “gene drive,” to limit loss of biodiversity and disease transmission caused by wild rodent populations. We previously showed that such a system of gene conversion from heterozygous to homozygous after a sequence targeted CRISPR/Cas9 double-strand DNA break (DSB) is feasible in the female mouse germline. In the male germline, however, all DSBs were instead repaired by end joining (EJ) mechanisms to form an “insertion/deletion” (indel) mutation. These observations suggested that timing Cas9 expression to coincide with meiosis I is critical to favor conditions when homologous chromosomes are aligned and interchromosomal homology-directed repair (HDR) mechanisms predominate. Here, using a Cas9 knock-in allele at the Spo11 locus, we show that meiotic expression of Cas9 does indeed mediate gene conversion in the male as well as in the female germline. However, the low frequency of both HDR and indel mutation in both male and female germlines suggests that Cas9 may be expressed from the Spo11 locus at levels too low for efficient DSB formation. We suggest that more robust Cas9 expression initiated during early meiosis I may improve the efficiency of gene conversion and further increase the rate of “super-mendelian” inheritance from both male and female mice.

This study shows that while Cas9 expression during meiosis I promotes genotype conversion - the mechanism underlying CRISPR ’gene drive’ - in both male and female mice, timing and high levels of Cas9 protein are critical to achieve robust efficiency.     

Efficient and specific generation of knockout mice using Campylobacter jejuni CRISPR/Cas9 system

The Streptococcus pyogenes CRISPR/Cas9 (SpCas9) system is now widely utilized to generate genome engineered mice; however, some studies raised issues related to off-target mutations with this system. Herein, we utilized the Campylobacter jejuni Cas9 (CjCas9) system to generate knockout mice. We designed sgRNAs targeting mouse Tyr or Foxn1 and microinjected into zygotes along with CjCas9 mRNA. We obtained newborn mice from the microinjected embryos and confirmed that 50% (Tyr) and 38.5% (Foxn1) of the newborn mice have biallelic mutation on the intended target sequences, indicating efficient genome targeting by CjCas9. In addition, we analyzed off-target mutations in founder mutant mice by targeted deep sequencing and whole genome sequencing. Both analyses revealed no off-target mutations at potential off-target sites predicted in silico and no unexpected random mutations in analyzed founder animals. In conclusion, the CjCas9 system can be utilized to generate genome edited mice in a precise manner.     

利用CRISPR/Cas9技术构建定点突变小鼠品系

CRISPR/Cas9技术是新近发展起来的对细胞和动物模型进行基因编辑的重要方法。本文利用DNA双链断裂(Double-strand breaks, DSBs)引起的同源重组(Homologous recombination, HR)依赖与非依赖的修复机制,建立基于CRISPR/Cas9核酸酶技术构建定点突变小鼠品系的技术体系。针对赖氨酸特异脱甲基化酶2b(Lysine (K)-specific demethylase 2b, Kdm2b)酶活关键位点对应的基因组DNA序列设计单一导向RNA(Single-guide RNA, sgRNA),通过与Cas9 mRNA共显微注射,分别得到Kdm2b基因发生移码突变的基因失活品系及关键位点氨基酸缺失的酶活突变型小鼠品系。此外,利用HR介导的修复机理,将黄素单加氧酶3(Flavin containing monooxygenases3, Fmo3)基因的sgRNA序列及对应的点突变单链寡脱氧核苷(Single strand oligonucleotides, ssODN)修复模板共注射到小鼠受精卵雄原核。对F₀小鼠基因测序分析显示,成功构建了Fmo3基因移码突变的基因敲除和单碱基定点突变的基因敲入小鼠,这些突变能够稳定遗传给子代。本研究利用CRISPR/Cas9技术,通过同源重组依赖与非依赖两种DNA损伤修复方式,成功构建了特定位点突变的小鼠品系。